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Abstract Objective: To assess the
influence of recipient’s and donor’s
factors as well as surgical events
on the occurrence of reperfusion
injury after lung transplantation.
Design and setting: Retrospective
study in the surgical intensive care
unit (ICU) of a university hospital.
Methods: We collected data on 60
lung transplantation donor/recipient
pairs from June 1993 to May 2001,
and compared the demographic,
peri- and postoperative variables of
patients who experienced reperfusion
injury (35%) and those who did
not. Results: The occurrence of
high systolic pulmonary pressure
immediately after transplantation
and/or its persistence during the
first 48 h after surgery was as-
sociated with reperfusion injury,
independently of preoperative values.
Reperfusion injury was associated
with difficult hemostasis during
transplantation (p = 0.03). Patients
with reperfusion injury were more
likely to require the administration
of catecholamine during the first
48 h after surgery (p = 0.014). The
extubation was delayed (p = 0.03)
and the relative odds of ICU mor-
tality were significantly greater
(OR 4.8, 95% CI: 1.06, 21.8) in
patients with reperfusion injury. Our
analysis confirmed that preexisting
pulmonary hypertension increased
the incidence of reperfusion injury
(p < 0.01). Conclusions: Difficulties
in perioperative hemostasis were
associated with reperfusion injury.
Occurrence of reperfusion injury was
associated with postoperative systolic
pulmonary hypertension, longer
mechanical ventilation and higher
mortality. Whether early recognition
and treatment of pulmonary hyper-
tension during transplantation can
prevent the occurrence of reperfusion
injury needs to be investigated.
Keywords Graft · Human · Ische-
mia–reperfusion injury · Organ trans-
plantation · Primary graft failure ·
Pulmonary hypertension
Introduction
Lung transplantation progressed from an early experimen-
tal stage to become the mainstay of therapy for end-stage
lung disease refractory to medical treatment. Unfortu-
nately, lung transplantation is limited by a significant
shortage of available organs: only one among five donor
organs is suited for transplantation since chest trauma,
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aspiration, or neurogenic pulmonary edema cause exces-
sive damage to the lung [1]. Seven to 15% of transplant
candidates die each year while waiting for suitable organs
in Switzerland [2]. After transplantation, 10–20% of the
patients die during the first 3 months due to infection,
cardiac failure and/or reperfusion injury (RI) [1, 3].
RI remains a serious complication in lung transplanta-
tion and may contribute to the early mortality and mor-
bidity [3, 4, 5]. Numerous terms and diagnostic criteria
are used to describe ischemia–reperfusion-induced lung in-
jury, and therefore the prevalence of the early graft dys-
function cannot be determined precisely; indeed, a large
majority of lung transplant recipients develop some degree
of perihilar edema during the immediate postoperative pe-
riod, and 15–35% of them will experience respiratory fail-
ure and require prolonged mechanical ventilation and phar-
macological support.
Prolonged ischemia [6], the type of preservation solu-
tion [7, 8] and previous pulmonary hypertension [3] all
seem to play an important role in the occurrence and the
severity of RI; however, there are few studies investigating
the risk factors for RI accounting simultaneously for sur-
gical events, donor and recipient characteristics. The pur-
pose of the present study was to investigate the effect of
donor’s characteristics, intraoperative variables, and recip-
ient’s characteristics on the development of RI.
Materials and methods
Patients
We collected data on a retrospective cohort of 65 consec-
utive lung graft recipients transplanted between June 1993
and May 2001 at the University Hospitals of Geneva.
There were 17 single lung transplantations (SLT) and 48
bilateral lung transplantations (BLT). Informed consent
for registry data use was obtained from the patients when
placed on the waiting list. Data abstractors were blind to
patient’s outcome. Age, sex, weight, height, underlying
disease, arterial blood gas and 6-min walking distance
were collected for all patients at the time they were put
on the transplantation list. Data on cardiac catheterization
(cardiac output, pulmonary arterial systolic and diastolic
pressure, pulmonary capillary wedge pressure) were
available for all patients with exception of eight young
recipients with cystic fibrosis.
Donor selection criteria
Lung donors were identified according to standard
selection criteria: < 60 years of age; PaO2/FiO2 ratio
> 300 mmHg with an inspired oxygen fraction of 1.0 and
positive end-expiratory pressure of 5 cmH2O, normal chest
X-ray; absence of abnormal findings at bronchoscopy; and
smoking history of less than 20 packs per year. Individuals
who failed to meet one of these criteria were eligible for
organ donation provided the remaining criteria were satis-
fied. Variables collected from donor charts included: age,
sex, weight, height, smoking habits, cause of death, last
PaO2/FiO2 ratio, chest X-ray findings, pre-explantation
ventilatory settings (duration of ventilation, peak inspi-
ratory pressure, positive end-expiratory pressure), length
of ICU stay, time from diagnosis of cerebral death to
explantation (duration of brain death), and medication
during the ICU stay (antibiotics, vasopressors).
Surgical technique and operative data
SLT was performed through a standard posterolateral
thoracotomy approach and BLT through an anterior
bilateral thoracosternotomy approach. Cardiopulmonary
bypass was used for all patients with primary pulmonary
hypertension and in selected cases with intraoperative
hemodynamic instability or inadequate gas exchange.
Ischemic time was calculated independently for each lung
as the interval from the start of the pulmonary artery
flush to reperfusion. Operative data included previous
thoracic surgery, surgical difficulties in dissection of the
native lung as reported in the surgical report, technical
difficulties in vascular and/or bronchial anastomosis,
difficulties of hemostasis as specifically mentioned in
the report, severe bleeding, blood transfusion, lung
preservation solution (modified Euro-Collins or low-
potassium dextran), use of cardiopulmonary bypass,
and ischemia time. Hemodynamic and ventilatory data
during surgery were retrieved from anesthesia reports
and included systemic and pulmonary pressures before
induction of general anesthesia, during surgery, and after
reperfusion of the transplanted lung. The use of vasopres-
sors, inhaled nitric oxide (NO), fluid administration and
transfusion, bleedings, and cardiac resuscitation during
transplantation were also recorded. Vasopressors and
inhaled NO were initiated in accordance with standard
clinical protocols: norepinephrine was administered to
maintain mean arterial pressure above 60 mmHg, and
dobutamine was added if the cardiac index was below
2.5 ml/min/m2. Inhaled NO was initiated in patients
with mean pulmonary artery pressure increase above
27 mmHg.
Postoperative management
All patients were intubated and ventilated for at least
12–24 h in the postoperative period. Criteria for liberation
from mechanical ventilation included a reduction in
ventilatory support to a pressure support < 10 cmH2O,
PEEP ≤ 5 cmH20, and FiO2< 40% with a PaO2 of at
least 8 kPa. In all patients, the immunosuppressant pro-
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tocol was as follows: 5-day course of antilymphocyte
globulins 5–15 mg/kg (ATGAM®; Upjohn, Kalama-
zoo, MI) with a triple immunosuppressive therapy
combining cyclosporine (CsA), azathioprine, and methyl-
prednisolone. CsA was given to achieve and maintain
a blood concentration of 200–250 ng/ml. Azathioprine
was administered at the dose of 2 mg/kg IV and then
replaced with mycophenolate mofetil (Cell cept®; Roche
Pharma, Basel, Switzerland) as soon as the patient was
enterally fed. Prednisone was initiated and maintained
at a dose of 0.5 mg/kg during the first 3 months. After
1996, basiliximabum (Simulect®; Novartis Pharma,
Basel, Switzerland) 20 mg on day 1 and day 4 replaced
antilymphocyte globulins. Hemodynamic and ventilatory
parameters were noted 1, 12, 24, and 48 h after admission
to the intensive care unit (ICU). Chest X-rays were
analyzed at 1, 12, 24, and 48 h after arrival in the ICU
and graded by two critical care physicians according
to the scoring system described by Anderson [9]. Dis-
agreements were resolved by a joint second reading to
achieve consensus. Briefly, each lung field was divided
into four regions (perihilar, apical, lateral and basilar)
and the degree of injury was assigned by a number
between 0 and 3 (0 = normal lung and 3 = extensive
alveolar infiltrate obscuring lung vessels with or without
air bronchograms). The cumulative score (0–12) for
each lung was the sum of the four regions. Time to
extubation, length of ICU and hospital stay, and mortality
in ICU, during hospital stay and after discharge were
recorded.
RI− (n = 39) RI+ (n = 21) p
Age (years) 47 ± 12 41 ± 17 0.25
Male/female 23/16 10/11 0.40
Height (cm) 168 ± 9 164 ± 14 0.65
Weight (kg) 60 ± 12 59 ± 20 0.76
Diagnosis, n (%)
Emphysema 24 (62) 3 (14) < 0.01
Pulmonary hypertension 1 (3) 8 (38) < 0.01
Idiopathic pulmonary fibrosis 3 (4) 3 (14) 0.42
Cystic fibrosis 7 (18) 4 (19) 0.92
Others 4 (10) 3 (14) 0.64
Preoperative variables, n (%)
PAP systolic (mmHg) 43 ± 19 61 ± 27 < 0.01
CO (l/min) 4.9 ± 1.1 4.5 ± 1.5 0.26
PaO2/FiO2 (mmHg) 270 ± 75 258 ± 58 0.58
PaCO2 (mmHg) 45.7 ± 11.2 43.5 ± 14.2 0.43
6 min walk (m) 266 ± 124 266 ± 122 0.83
SaO2 (%) 83 ± 13 86 ± 8 0.32
Previous surgery 5 (13) 5 (24) 0.28
Steroids > 20 mg/day 4 (10) 1 (5) 0.46
Home O2 21 (54) 10 (48) 0.64
Home NIV 1 (3) 5 (24) < 0.01
PAP pulmonary arterial pressure, CO cardiac output, NIV non invasive ventilation
Table 1 Characteristics of
recipients (mean ± SD, unless
otherwise specified)
Bronchoscopy with bronchoalveolar lavage (BAL) was
routinely performed after 48 h. Cell count and gram stain
results were collected.
Definition of reperfusion injury
RI was defined as being present when the patient had
a chest X-ray score ≥ 6 (diffuse alveolar opacities),
a PaO2/FiO2 ratio ≤ 200 mmHg during the first 48 h post-
operatively, and no secondary cause of graft dysfunction
was identified [3].
Statistical analysis
A complete case analysis was performed: five patients that
had missing data were excluded from all analyses. De-
scriptive statistics were used to examine the distribution of
continuous and categorical variables among patients with
and without reperfusion injury and the two groups were
compared using unpaired Student t-test or Chi-square, as
appropriate. Multiple logistic regression was used to es-
timate the odds ratios associated with reperfusion injury
and adjust for potential confounders (age, gender and body
weight). For analysis of repeated observations, general-
ized estimating equations (GEE) with robust estimate of
the variance were used to account for dependence in the
data. The level of significance was set at an alpha of 0.05
for all analyses. All data are expressed as mean ± SD.
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Results
Among the 60 patients analyzed, 21 (35%; 95% CI 0.23,
0.48) recipients developed RI. Demographic characteris-
tics of all patients by presence or absence of RI are shown
in Table 1. Patients with and without RI were not different
with regard to age, gender or body mass index. The time
on waiting list was not different between the two groups.
Among patients with RI, eight had a history of primary
or secondary pulmonary hypertension while of those
without RI, only one had such history (p < 0.01). Three
(11%) out of 27 patients with emphysema developed
RI; the remaining 24 patients with emphysema represent
the 62% of all patients without RI (p < 0.01) (Table 1).
Patients with history of emphysema had a significantly
RI− (n = 39) RI+ (n = 21) p
Age (years) 30 ± 13.4 33 ± 14.5a 0.35
Male/female 24/15 11/10 0.49
Height (cm) 170 ± 10 172 ± 12.7 0.57
Weight (kg) 66 ± 10 67 ± 14 0.66
Smokers, n (%) 8 (20)b 5 (24) 0.77
CMV+, n (%) 21 (54) 7 (33) 0.13
During ICU stay
MV (days) 2 ± 1.3 1.6 ± 0.8 0.14
Death-OR (h) 12.8 ± 7.4 11.7 ± 3.8 0.54
Use of antibiotics, n (%) 14 (36) 2 (9) 0.03
Use of vasopressors, n (%) 28 (72) 16 (76) 0.71
Positive airways culture, n (%) 2 (5) 1 (5) 0.95
Diabetes insipidus, n (%) 23 (59) 12 (57) 0.61
Causes of cerebral death, n (%)
Neurotrauma 22 (56) 11 (57) 0.76
Intracerebral bleeding 10 (26) 7 (33) 0.53
Subarachnoidal bleeding 4 (10) 1 (5 ) 0.46
Others 3 (8) 2 (10) 0.81
Comorbidities, n (%)
Chest trauma 6 (15) 5 (24) 0.42
Cardiac arrest 2 (5) 4 (19) 0.09
a One patient > 60 years of age
b One patient smoking > 20 packs per year
MV Mechanical ventilation, CMV cytomegalovirus, Death-OR time between diagnosis of cerebral death
and organ explantation
Table 2 Characteristics of
donors (mean ± SD, unless
otherwise specified
RI− (n = 39) RI+ (n = 21) p
Single lung transplantation 16 (41) 5 (24) 0.10*
Hemostasis difficulties 8 (20) 10 (48) 0.03
Mobilization difficulties 10 (26) 6 (29) 0.81
Previous thoracic surgery 5 (13) 6 (29) 0.13
Cardiopulmonary bypass 10 (26) 10 (48) 0.09
Blood transfusion > 2 BU 17 (44) 9 (43) 0.68
Ischemia time (h), 1 lung/2 lungs 3.5/4.4 3.6/4.3 0.82
Preservation solution (EC/LPD) 27/12 15/6 0.86
BU blood units, EC Euro-Collins, LPD low-potassium dextran
* single vs. double lung transplantation
Table 3 Frequency of surgical
events, n (%)
lower risk of RI (odds ratio 0.10; 95% CI 0.02, 0.42).
Among the preoperative variables, only pulmonary artery
pressure was significantly different between patients
with and without RI. None of the donor variables were
associated with a significant risk of RI (Table 2). Five
patients (29%) with SLT developed RI, and 16 patients
(33%) with BLT developed RI (p = 0.10, Table 3). Among
the surgical events that were analyzed, difficulties of
hemostasis reported on the surgical record were associated
with a greater risk of RI: 10 out of 21 patients with RI
had hemostasis difficulties, whereas 8 out of 39 patients
without RI had hemostasis difficulties (OR 3.5; 95%
CI 0.95, 13.1; p = 0.03). These difficulties consisted in
tendency to diffuse bleeding, without major loss of blood
but requiring a meticulous surgical hemostatic measure.
561
Fig. 1 Time course of systolic
pulmonary artery pressure
(PAP), PaO2/FiO2 ratio and
cumulative chest X-ray scores in
patients with RI (squares) and
without RI (diamonds) during
the first 48 h after surgery. PAP
was significantly higher in
patients with RI during the first
48 h after transplantation
regardless of history of
pulmonary hypertension. It is
noteworthy that the PaO2/FiO2
ratio appears lower in the RI
group already during the
intraoperative period, suggesting
an early onset of RI. The
PaO2/FiO2 ratio was omitted
from the analysis as it represents
one of the components of the RI
definition. *p < 0.01, generalized
estimating equations, with
robust standard errors
Cardiopulmonary bypass, blood transfusion, type of
preservation solution, and duration of ischemic time did
not differ between patients who presented with RI and
those who did not (Table 3). Postoperatively, the odds ratio
of RI was 1.14 (95% CI 1.04, 1.26) for 1 mmHg difference
in systolic pulmonary artery pressure. This remained
significant regardless of preoperative pulmonary hyperten-
sion, and after adjustment for catecholamine requirement
(Fig. 1). It is interesting to note that one patient with
preexisting pulmonary hypertension who did not experi-
ence RI presented low postoperative pulmonary arterial
pressures, similar to the group of patients without RI.
Systemic pressures and cardiac output did not differ
between patients with and those without RI, although pa-
tients with RI were more likely to require the adminis-
tration of catecholamines: 10 (17%) patients with RI vs.
6 (10%) without RI required catecholamines at 12 h post-
transplantation (p = 0.013), 12 (20%) patients with RI vs.
3 (5%) without RI at 24 h (p < 0.01), and 5 (8%) patients
with RI vs. 1 (2%) without RI at 48 h (p = 0.014). The odds
ratio for RI was 4.31 (95% CI 1.08, 17.25) for patients re-
quiring catecholamines at 24 h compared with those who
did not.
The number of neutrophils in the BAL was signifi-
cantly higher in patients developing RI (Fig. 2) and was
positively correlated with the severity score of the lung
infiltrate on the chest X-ray (r = 0.548, p < 0.01).
The time to extubation was significantly longer
for patients with RI than for patients without RI
(6.05 ± 5.74 days vs. 2.78 ± 3.7 days; p = 0.03); the
ICU length of stay did not differ significantly between
the two groups (15 ± 15 days in the RI group vs.
10.8 ± 7.6 days in the non-RI group; p = 0.6).
ICU mortality was higher in patients with RI:
6/21 (28%) in patients with RI vs. 3/39 (8%) in patients
without RI (OR of death 4.8; 95% CI 1.06, 21.8). How-
ever, there was no difference in the cumulative mortality
between the two groups after 6 and 12 months of follow-
Fig. 2 Box-and-whiskers plot displaying polymorphonuclear neu-
trophils (PMN) in bronchoalveolar lavage fluid of patients with
(RI+) and without (RI–) reperfusion injury, expressed in percentage.
*p < 0.01, comparing patients with and without RI
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up: 8/21 (38%) vs. 9/39 (23%) at 6 months (p = 0.2), and
8/21 (38%) vs. 10/39 (26%) at 12 months (p = 0.3).
Discussion
In this retrospective study, we investigated the effect of
donor, respective recipient, and operative characteristics on
the development of RI after lung transplantation. Similarly
to previously published reports, we observed that the rate
of RI was 35% [3, 7]. Multiple factors were found to be
associated with its occurrence.
Difficulties of surgical hemostasis were associated
with increased risk of RI, but not with greater requirement
for blood or platelets transfusion or greater postoperative
bleeding. The retrospective design of the present study
does not allow exploring the nature of possible coagu-
lation defects during surgery. However, this finding is
consistent with recent data showing that disorders of the
complex thrombin/antithrombin III are related to early
graft dysfunction [10, 11].
Postoperatively, the increase and/or the persistence of
preexisting high pulmonary systolic arterial pressure im-
mediately and during the first 48 h after transplantation
was associated with increased risk of RI, independently of
previous pulmonary pressure levels. It is interesting to note
that after adjustment for history of pulmonary hyperten-
sion, the occurrence of postoperative pulmonary hyperten-
sion remained significantly associated with RI, suggesting
that postoperative factors could also contribute to RI. As
shown by other investigators [3, 12, 13], we found that pre-
existing pulmonary arterial hypertension was associated
with increased risk of RI, while recipients with pulmonary
emphysema were less likely to develop RI.
There was increased short-term (ICU) mortality but not
mid-term (3 months) mortality associated with RI.
The main limitation of our study is the small size of
the sample; therefore, our findings may not be generaliz-
able to other settings. However, all patients were treated
at the same institution and received uniform treatment. In
addition, despite the large number of variables collected,
other unmeasured factors may influence the development
of RI.
Increased level of interleukin-8 (IL-8) in the donor
BAL has been described to be associated with the develop-
ment of severe early graft dysfunction [14]. We could not
investigate intrapulmonary factors such as IL-8 in donors’
lung because of the retrospective nature of our study.
Thus, we cannot exclude the possibility that processes
related to the development of the pulmonary hypertension
and RI were already ongoing in the donors.
Preoperative factors. In order to determine the influ-
ence of donor and recipient characteristics, some authors
compared early graft function in paired recipients, each re-
ceiving one lung from the same donor. Sommers et al. [12]
observed that donor-related characteristics influenced only
early lung allograft function within 24 h after transplan-
tation. Indeed, donor age, length of donor hospitalization,
and primary pulmonary hypertension influenced the risk
of primary graft failure in their study. We did not observe
an association between RI and donor age or length of hos-
pitalization prior to explantation. This discrepancy could
possibly arise from the different definitions of graft dys-
function in the two studies.
There is a controversy regarding the effect of head
trauma of the donor on the development of RI. Fisher
et al. [15] described an enhanced inflammatory state and
graft failure when donors suffered traumatic intracranial
hemorrhage. More recently, Ciccone et al. [16] observed
no difference in the PaO2/FiO2 ratio of recipients between
donors with traumatic and nontraumatic brain injury. Our
data support the latter findings that the risk of RI does
not differ between patients with and without neurotrauma
(Table 2).
Perioperative factors. Snell et al. [17] observed that
the duration of ischemia was a significant risk factor for
graft dysfunction. In our study, because of the small size
of our country and the short transport time, the ischemia
time was overall less than 6 h. This lack of variation of
ischemia duration could explain why we did not observe
any effect of ischemic time on RI. Extracellular preserva-
tion solutions have been found to be protective against the
development of RI [7, 18]. The potential beneficial role of
low-potassium dextran could not be confirmed in our study
because of the small numbers of graft treated with this so-
lution.
Postoperative factors. In the postoperative course, pro-
longed catecholamine requirement and longer duration of
intubation were also found to be positively associated with
the risk of RI. The presence of inflammation was indi-
rectly confirmed by the higher polymorphonuclear neu-
trophil count in the BAL of patients with RI than in those
without RI. Furthermore, a positive correlation was ob-
served between the number of neutrophils in the BAL and
the extent of the pulmonary infiltrates, which supports the
inflammatory nature underlying RI. As shown by de Perrot
et al. [19], a possibly increased inflammatory response was
observed in patients with RI with accompanying higher
hemodynamic instability and prolonged requirement for
pharmacological support.
The retrospective nature of our study does not permit
a direct biological explanation for the present findings.
However, based on prior knowledge we could speculate
that RI is characterized by: (1) Early impairment in the co-
agulation system, as indicated by perioperative hemostasis
difficulties; (2) the activation of inflammatory cascades, as
indicated by the prolonged requirement of hemodynamic
support; and (3) a possible impairment in the regulation of
the endogenous nitric oxide production that accompanies
the endothelial dysfunction lead to a loss of NO-dependant
vasodilatation [20], as indicated by the raised pulmonary
pressure. Indeed, Thabut et al. [21] showed that inhaled
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nitric oxide supplemented by intravenous pentoxifylline at
reperfusion reduced the occurrence of RI.
Despite the several limitations of our study, the finding
of a raised pulmonary hypertension early after transplanta-
tion associated with RI seems to be important. Due to the
observational nature of the present study, we cannot infer
the cause. Whether early recognition and treatment of pul-
monary hypertension during and immediately after trans-
plantation can prevent the occurrence of RI needs to be
investigated. In addition, our study provides data for fur-
ther research into the mechanisms that lead to RI. Com-
parison across studies was particularly difficult due to the
nonuniform definition of graft failure. For future studies
a consensus on the definition of RI would be highly desir-
able.
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